Taiho hires head from BMS
pharmafile | May 29, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | BMS, taiho, whiten
Japan-based pharma firm Taiho Oncology has appointed Tim Whitten to the position of senior vice president and chief commercial officer.
Prior to joining Taiho Oncology Whitten spent 17 years at Bristol-Myers Squibb where he served in various sales, marketing, and strategic planning roles including VP, marketing, US oncology and immunology; and VP, global Marketing, oncology, immunology, and pulmonary diseases.
Whitten was previously employed by Pharmacyclics where he served in various roles, including senior VP marketing and sales and business development. From 2006 to 2012, he served as president and chief executive of Transave/Insmed.
“Taiho Oncology has been making significant changes to its operations in preparation for the potential commercialisation of our lead product, TAS-102, most importantly the appointment of Tim Whitten as our chief commercial officer,” said Eric Benn, president and chief executive of Taiho Oncology.
Related Content
Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …
BMS acquires Mirati Therapeutics for $4.8bn
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …
BMS shares new research and development plans at the company’s R&D day
Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …